Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
23.1 USD | +0.90% |
|
-16.18% | +10.60% |
Jun. 04 | Oppenheimer Initiates Cartesian Therapeutics With Outperform Rating, $50 Price Target | MT |
May. 24 | Mizuho Securities Starts Cartesian Therapeutics With Buy Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.60% | 407M | |
+14.98% | 122B | |
+19.83% | 113B | |
+8.24% | 22.84B | |
-20.44% | 20.72B | |
-16.19% | 16.51B | |
-12.94% | 16.39B | |
-44.35% | 15.83B | |
+1.39% | 13.49B | |
+68.93% | 11.67B |
- Stock Market
- Equities
- RNAC Stock
- News Cartesian Therapeutics, Inc.
- Transcript : Selecta Biosciences, Inc., Q2 2020 Earnings Call, Aug 06, 2020